合富（中国）医疗科技股份有限公司 2025 年第三季度报告 证券代码：603122 证券简称：合富中国 合富（中国）医疗科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 181,204,123.44 | -21.27 | ...

Core Points - The Shanghai Composite Index is currently at 3993.52 points, slightly below the half-year line with a change of -0.09% [1] - A total of 66 A-shares have surpassed the half-year line today, with notable stocks showing significant deviation rates [1] Group 1: Stock Performance - The stock with the highest deviation rate is Libang Instruments, with a deviation rate of 14.95% and a daily increase of 16.28% [1] - Tax Friend Co. and Founder Motor follow with deviation rates of 6.81% and 6.27%, respectively, both showing daily increases of 10.00% and 9.98% [1] - Other notable stocks include Cuihua Jewelry and Furuite Equipment, with deviation rates of 4.94% and 4.50% respectively [1] Group 2: Trading Volume and Market Activity - The total trading volume of A-shares today reached 10089.87 billion yuan [1] - The turnover rate for Tax Friend Co. is notably high at 46.64%, indicating strong trading activity [1] - Other stocks with significant turnover rates include Libang Instruments at 10.82% and Cuihua Jewelry at 8.21% [1]

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Viewpoint - The company held a half-year performance briefing on October 16, 2025, to communicate with investors and address their inquiries regarding business strategies and performance challenges [1][8]. Group 1: Performance Briefing Details - The performance briefing was attended by key executives including the Chairman, General Manager, and independent directors, facilitating interactive communication with investors [1]. - The briefing was conducted online, allowing for pre-submitted questions from investors to be addressed during the session [1]. Group 2: Investor Questions and Company Responses - The company is focused on introducing globally unique products in mainland China while also considering local production options, such as the "Maitaiwei" platform [2]. - The "Maitaiwei" platform has received positive feedback from clients, demonstrating its effectiveness in providing digital medical solutions and facilitating remote guidance for complex surgeries [2]. - The decline in revenue is attributed to national procurement price reduction policies, impacting sales and profits, with the company implementing strategies to mitigate these effects [3]. - The company has consistently returned value to shareholders through cash dividends, exceeding 200 million RMB over four years, and aims to enhance operational efficiency and core competitiveness [4]. - The company is exploring various strategies to strengthen existing customer relationships and market share, including leveraging AI technology and enhancing collaboration with medical experts [5]. - The uncertainty of US-China trade tariffs has affected the broader market environment, but the company's operations and employee confidence remain stable [6].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-040 合富（中国）医疗科技股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"、"合富中国"或"合 富 "） 于 2025 年 10 月 16 日 （ 星 期 四 ） 11:30-12:30 在 价 值 在 线 网 站 （https://www.ir-online.cn/）通过网络文字互动的形式召开了公司 2025 年半 年度业绩说明会，现将具体情况公告如下： 一、本次业绩说明会召开情况 公司于 2025 年 10 月 16 日（星期四）11:30-12:30 召开了公司 2025 年半年 度业绩说明会，董事长 李惇先生、董事 总经理 财务总监王琼芝女士、独立董 事 蔡彦卿先生、独立董事 翁文能先生、董事会秘书 朱莺女士出席了本次业绩 说明会，与投资者进行网络互动交流和沟通。本次业绩说明会召开前，公司已通 过公司投资者关系邮箱 ir_cowealth ...

Core Viewpoint - The company, HeFu China, reported a significant decline in consolidated revenue for the first nine months of the year, indicating potential challenges in its business performance [1] Financial Performance - The consolidated revenue for HeFu China from January to September reached 549 million yuan, which represents a 22.8% decrease compared to the same period last year [1]

合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-9 月合并营业收入人民币 54,886.23 万元，较去年同期下降 22.80%。 2025 年 1-9 月累计营业收入简报 2025 年 10 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 特此公告。 证券代码：603122 证券简称：合富中国 公告编号：临 2025-039 合富（中国）医疗科技股份有限公司董事会 合富（中国 ...